Affiliation:
1. Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at Gothenburg University , Bruna stråket 16, 413 45 Gothenburg , Sweden
2. Core Facilities—Experimental Biomedicine, Sahlgrenska Academy , Gothenburg , Sweden
3. Department of Cardiology, Sahlgrenska University Hospital , Gothenburg , Sweden
Abstract
Abstract
Aims
Adequate animal models are necessary to understand human conditions, such as takotsubo syndrome (TS) characterized by the heart's transient regional wall motion abnormalities. This study aims to develop a reproducible, low-mortality TS model that closely mimics the human condition and addresses the limitations of existing models.
Methods and results
We conducted six experiments using 309 Sprague Dawley rats, each approximately 300 g and aged 7–8 weeks. Initially, we replicated an established model using intraperitoneal isoprenaline injections. Subsequent experiments varied the doses and infusion durations of intravenous isoprenaline and assessed the effects of sex, strain, and breeder on the development of reversible akinetic segments. High-resolution echocardiography monitored the regional wall motion over 30 days to correlate with histological changes. Increasing the isoprenaline dose and the infusion time significantly enhanced akinesia (P < 0.01), resulting in pronounced apical ballooning observed in three-dimensional imaging. Akinesia peaked at 6 h post-infusion, with recovery observed at 24 h; most rats recovered from akinetic segments within 48–72 h. Optimizing the mode of administration, dose, and duration achieved a TS-like phenotype in 90% of cases, with a 16.7% mortality rate. Histological examinations confirmed that myocardial injury occurred, independent of apical ballooning.
Conclusion
This study presents a refined TS model that reliably replicates the syndrome's key features, including morphological and electrocardiographic changes, demonstrating its transient nature with high fidelity and reduced mortality. The model's reproducibility, evidenced by consistent results across trials, suggests its potential for broader application pending further validation.
Funder
Swedish Research Council
Swedish Heart-Lung Foundation
ALF
Swedish Society for Medical Research
Publisher
Oxford University Press (OUP)